Data shown at the AAAAI annual meeting showed that chronic spontaneous urticaria activity and DLQI rankings were higher following dupilumab treatment.
In data presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2023 Annual Meeting in San Antonio, TX, Dermatology Life Quality Index (DLQI) and activity rankings for patients with chronic spontaneous urticaria (CSU) were improved for those given dupilumab.1
Chronic spontaneous urticaria (CSU) is a condition characterized by the recurrence of itchy wheals and/or angioedema that may persist for over 6 weeks.
It is a chronic inflammatory illness that has a negative effect on a patient's quality of life. Unfortunately, numerous patients continue to suffer from CSU symptoms.
This research was authored by Marcus Maurer, MD, from Charite-Universitatsmedizin Berlin in Germany. Maurer and colleagues conducted a phase 3 clinical trial titled LIBERTY-CSU CUPID Study A.
The investigators’ research was designed to assess the safety and effectiveness of dupilumab in treating CSU patients aged ≥6 years who had remained symptomatic although they had taken H1-antihistamines
The first group received add-on dupilumab 300 mg (for adults/adolescents ≥60 kg) or 200 mg (for adolescents <60 kg/children ≥30 kg) every 2 weeks through the use of subcutaneous injections. The second group were given a matching placebo.
The trial lasted for 24 weeks, and the efficacy of the treatment was assessed based on the Urticaria Activity Score over a single week (UAS7; score range: 0-42).
The research team measured quality of life outcomes for patients >16 years old using the DLQI (range: 0-30, with higher scores being lower life quality).
Overall, the team noted that the mean UAS7 values at baseline for dupilumab and placebo were 31.9 and 30.8, respectively. After 24 weeks, the least squares (LS) mean change from baseline was found to be significantly greater for patients given dupilumab than for those given the placebo, with values of -20.5 and -12.0, respectively.
The investigators added that the difference between both groups was -8.5, and the P-value was 0.0003. The mean DLQI scores at baseline for dupilumab and placebo were also noted as being 13.5 and 15.3, respectively.
At 24 weeks, the LS mean change from baseline was noted by the team as being substantially greater for dupilumab patients than for those given the placebo, with values of -10.8 and -7.6, respectively.
The researchers found that the difference between the two groups was -3.2, and the nominal P-value was 0.0026.